Patents by Inventor Carlos Montero Salgado

Carlos Montero Salgado has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9296710
    Abstract: The present invention provides novel mGlu2 agonists useful in the treatment of bipolar disorder, schizophrenia, and generalized anxiety disorder.
    Type: Grant
    Filed: June 7, 2012
    Date of Patent: March 29, 2016
    Assignee: Eli Lilly and Company
    Inventors: Teresa Tse Ki Man, James Allen Monn, Carlos Montero Salgado, Lourdes Prieto, David Edward Tupper, Lesley Walton
  • Publication number: 20140113944
    Abstract: The present invention provides novel mGlu2 agonists useful in the treatment of bipolar disorder, schizophrenia, and generalized anxiety disorder.
    Type: Application
    Filed: June 7, 2012
    Publication date: April 24, 2014
    Applicant: ELI LILLY AND COMPANY
    Inventors: Teresa Tse Ki Man, James Allen Monn, Carlos Montero Salgado, Lourdes Prieto, David Edward Tupper, Lesley Walton
  • Patent number: 8318184
    Abstract: The present invention provides novel mGlu2 agonists useful in the treatment of bipolar disorder, schizophrenia, depression, and generalized anxiety disorder.
    Type: Grant
    Filed: December 15, 2010
    Date of Patent: November 27, 2012
    Assignee: Eli Lilly and Company
    Inventors: James Allen Monn, Lourdes Prieto, Lorena Taboada Martinez, Carlos Montero Salgado, Bruce William Shaw
  • Publication number: 20110152334
    Abstract: The present invention provides novel mGlu2 agonists useful in the treatment of bipolar disorder, schizophrenia, depression, and generalized anxiety disorder.
    Type: Application
    Filed: December 15, 2010
    Publication date: June 23, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: James Allen MONN, Lourdes PRIETO, Lorena TABOADA MARTINEZ, Carlos Montero SALGADO, Bruce William SHAW
  • Publication number: 20080227839
    Abstract: The present invention provides kinase inhibitors of Formula I:
    Type: Application
    Filed: January 21, 2005
    Publication date: September 18, 2008
    Inventors: Rosanne Bonjouklian, Robert Dean Dally, Alfonso de Dios, Mirian Filadelfa del Prado Catalina, Carmen Dominguez-Fernandez, Carlos Jaramillo Aguado, Beatriz Lopez de Uralde-Garmendia, Carlos Montero Salgado, Timothy Alan Shepherd
  • Patent number: 7320995
    Abstract: The present invention provides kinase inhibitors of Formula I: wherein W represents inter alia imidazol, oxazol, pyrazol, thiazol as triazol, which are substituted by phenyl or thienyl.
    Type: Grant
    Filed: July 31, 2003
    Date of Patent: January 22, 2008
    Assignee: Eli Lilly and Company
    Inventors: Rosanne Bonjouklian, Jose Eugenio De Diego Gomez, Alfonso De Dios, Chafiq Hamdouchi Hamdouchi, Tiecho Li, Beatriz Lopez De Uralde Garmendia, Michal Vieth, Jeremy Schulenberg York, Robert Dean Dally, Miriam Filadelfa Del Prado Catalina, Carlos Jaramillo Aguado, Luisa Maria Martin-Cabrejas, Carlos Montero Salgado, Sheila Pleite Selgas, Concepcion Sanchez-Martinez, Timothy Alan Shepherd, James Howard Wikel
  • Patent number: 7038077
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
    Type: Grant
    Filed: January 9, 2002
    Date of Patent: May 2, 2006
    Assignee: Eli Lilly and Company
    Inventors: Anne Hollins Dantzig, James Allen Monn, Stephanie Ann Sweetana, Ana Belen Bueno Melendo, Alfonso De Dios, Carmen Dominguez-Fernandez, Marc Francis Herin, Luisa Maria Martin-Cabrejas, Jose Alfredo Martin, Maria Angeles Martinez-Grau, Carlos Montero Salgado, Concepcion Pedregal-Tercero
  • Publication number: 20050272791
    Abstract: The present invention provides kinase inhibitors of Formula I: wherein W represents inter alia imidazol, oxazol, pyrazol, thiazol as triazol, which are substituted by phenyl or thienyl. The disclosed compounds inhibit p-38 kinase and are useful in the treatment of metastasis or rheumatoid arthritis.
    Type: Application
    Filed: July 31, 2003
    Publication date: December 8, 2005
    Applicant: Eil Lilly and Company
    Inventors: Rosanne Bonjouklian, Jose De Diego Gomez, Alfonso De Dios, Chafiq Hamdouchi, Tiecho Li, Beatriz De Uralde Garmendia, Michal Vieth, Jeremy York, Robert Dally, Miriam Del Prado Catalina, Carlos Jaramillo Aguado, Luisa Martin-Cabrejas, Carlos Montero Salgado, Sheila Pleite Selgas, Concepcion Sanchez-Martinez, Timothy Shepherd, James Wikel
  • Publication number: 20040248963
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs of formula (I) wherein the residues R11, R12 and R13 are as defined in claim 1. The invention further relates to processes for the preparation of the compounds of formula (I), and to pharmaceutical compositions for the treatment of neurological and psychiatric disorders comprising said compounds.
    Type: Application
    Filed: April 30, 2004
    Publication date: December 9, 2004
    Inventors: Ana Belen Bueno Melendo, Alfonso De Dios, Carmen Dominguez-Fernandez, Mark Francis Herin, Luisa Maria Martin-Cabrejas, Jose Alfredo Martin, Maria Angeles Martinez-Grau, Steven Marc Massey, James Allen Monn, Carlos Montero Salgado, Concepcion Pedregal-Tercero, Matthew John Valli
  • Publication number: 20040176459
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
    Type: Application
    Filed: December 10, 2003
    Publication date: September 9, 2004
    Inventors: Ana Belen Bueno Melendo, Alfonso De Dios, Carmen Dominguez-Fernandez, Luisa Maria Martin-Cabrejas, Jose Alfredo Martin, Carlos Montero Salgado, Concepcion Pedregal-Tercero, Rafael Ferritto Crespo, Marc Francis Herin, Maria Angeles Martinez-Grau, Steven Marc Massey, James Allen Monn, Matthew John Valli
  • Publication number: 20040138304
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
    Type: Application
    Filed: January 26, 2004
    Publication date: July 15, 2004
    Inventors: Anne Hollins Dantzig, James Allen Monn, Stephanie Ann Sweetana, Ana Belen Bueno Melendo, Alfonso De Dios, Carmen Dominguez-Fernandez, Marc Francis Herin, Luisa Maria Martin-Cabrejas, Jose Alfredo Martin, Maria Angeles Martinez-Grau, Carlos Montero Salgado, Concepcion Pedregal-Tercero
  • Publication number: 20040122001
    Abstract: This invention relates to compounds of formula (I) where R1 to R12, —W—V—, —X—Y—, m and n have the values defined in claim 1, their preparation and use as pharmaceuticals.
    Type: Application
    Filed: January 16, 2004
    Publication date: June 24, 2004
    Inventors: Javier Agejas-Chicharro, Ana Belen Bueno Melendo, Nicholas Paul Camp, Jeremy Gilmore, Alma Maria Jimenez-Aguado, Carlos Lamas-Peteira, Alicia Marcos-Llorente, Michael Philip Mazanetz, Carlos Montero Salgado, Graham Henry Timms, Andrew Caerwyn Williams